ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1263

Impact of Cardiovascular Risk on the Diagnostic Accuracy of the Ultrasound Halo Score for Giant Cell Arteritis

Juan Molina1, KATERINE FABIOLA LOPEZ GLORIA2, Isabel Castrejon3, Juan Carlos Nieto González1, Julia Martinez-Barrio1, Ana M Anzola Alfaro4, Javier Rivera4 and José María Älvaro-Gracia1, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Madrid, Spain, 3Hospital Universitario Gregorio Marañón, Madrid, Spain, 4Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: To evaluate the impact of cardiovascular risk (CVR) on the diagnostic accuracy of the ultrasonographic (US) Halo Score in patients with suspected giant cell arteritis (GCA)

Methods: Retrospective observational study of patients referred to our US fast track clinic with suspected GCA for a 2-years period. The intima media thickness (IMT) of cranial and extra-cranial arteries and the Halo Score was determined to assess the extent of vascular inflammation. The European Society of Cardiology Guidelines on CV Disease Prevention were used to define different categories of CVR and patients were classified according to the Systemic Coronary Risk Evaluation (SCORE). The gold standard for GCA diagnosis was clinical confirmation after 6-month follow-up.

Results: Of the 157 patients included, 47(29.9%) had GCA after 6-month follow-up. Baseline characteristics of patients are shown in Table 1. Extra-cranial artery IMT was significantly higher in patients with high/very high CVR than in those with low/moderate CVR, but only among patients without GCA. Non-GCA patients with high/very high CVR had also a significantly higher Halo Score in contrast with low/moderate CVR [9.38(5.93) vs 6.16(5.22); p=0.007] (Table 2). The area under the ROC curve of the Halo Score to identify GCA was 0.835 (CI95% 0.756-0.914), slightly greater in patients with low/moderate CVR (0.965 [CI95% 0.911-1]) versus patients with high/very high CVR (0.798 [CI95% 0.702-0.895]) (Figure 1). A statistically weak positive correlation was found between the Halo Score and the SCORE (r 0.245;p=0.002).

Conclusion: Elevated CVR may influence the diagnostic accuracy of the US Halo Score for GCA. Thus, CVR should be taken into consideration in the US screening for GCA.

Supporting image 1

Table 1. Clinical, laboratory variables, and US findings in patients with or without GCA.
Abbreviations: GCA: giant cell arteritis; PMR: polymyalgia rheumatica; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; US: ultrasound; HDL: high density lipoprotein; LDL: low density lipoprotein; SD: standard deviation

Supporting image 2

Table 2. Measurements of IMT in cranial and extracranial arteries and Halo Score values according to CVR. SD: standard deviation

Supporting image 3

Figure 1. Diagnostic accuracy of the Halo Score for a clinical diagnosis of GCA after 6 months follow-up in (A) all LVV suspected patients, (B) patients with high to very high CVR and (C) patients with low to moderate CVR. Youden index was used to determine the optimal cut-off points. AUC, area under the curve, LR+, positive likelihood ratio; LR−, negative likelihood ratio; ROC, receiver operating characteristic; Sens, sensitivity; Spec, specificity


Disclosures: J. Molina, None; K. LOPEZ GLORIA, None; I. Castrejon, None; J. Nieto González, None; J. Martinez-Barrio, None; A. Anzola Alfaro, None; J. Rivera, None; J. Älvaro-Gracia, None.

To cite this abstract in AMA style:

Molina J, LOPEZ GLORIA K, Castrejon I, Nieto González J, Martinez-Barrio J, Anzola Alfaro A, Rivera J, Älvaro-Gracia J. Impact of Cardiovascular Risk on the Diagnostic Accuracy of the Ultrasound Halo Score for Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-cardiovascular-risk-on-the-diagnostic-accuracy-of-the-ultrasound-halo-score-for-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-cardiovascular-risk-on-the-diagnostic-accuracy-of-the-ultrasound-halo-score-for-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology